Alzheimer's disease (AD) is a neurodegenerative condition that affects a large number of elderly people worldwide and has a high social and economic impact. The diagnosis of AD in early stage can significantly improve the evolution and prognosis of the disease. We report the use of A Disintegrin And Metalloprotease 10 (ADAM10) as a blood biomarker for the early diagnosis of AD. A simple, low-cost, sensitive, and disposable microfluidic platform (DμP) was developed for ADAM10 detection in plasma and cerebrospinal fluid based on electrochemical immunosensors. The assay was designed to accurately detect ADAM10 in serum, with a limit of detection of 0.35 fg/mL. ADAM10 was detected in subjects divided into cognitively healthy subjects, subjects with mild cognitive impairment, and AD patients in different disease stages. An increase in protein levels was found throughout the disease, and good DμP accuracy in differentiating individuals was observed. The DμP provided significantly better sensitivity than the well-established enzyme-linked immunosorbent assay test. ADAM10 and its detection using the DμP were proven to be an alternative tool for the early diagnosis and monitoring of AD, bringing new exciting possibilities to improve the quality of life of AD patients.

中文翻译：

---

使用一次性电化学微流控平台对血液中的阿尔茨海默氏病进行早期诊断。

阿尔茨海默氏病（AD）是一种神经退行性疾病，会影响世界范围内的大量老年人，并具有很高的社会和经济影响。早期诊断AD可以显着改善疾病的发展和预后。我们报告使用A整联蛋白和金属蛋白酶10（ADAM10）作为血液生物标志物用于AD的早期诊断。开发了一种简单，低成本，灵敏且可抛弃的微流体平台（DμP），用于基于电化学免疫传感器的血浆和脑脊髓液中的ADAM10检测。该测定旨在准确检测血清中的ADAM10，检测极限为0.35 fg / mL。在分为认知健康受试者，轻度认知障碍受试者和处于不同疾病阶段的AD患者中检测到ADAM10。在整个疾病中发现蛋白质水平增加，并且在区分个体中观察到良好的DμP准确性。与公认的酶联免疫吸附试验相比，DμP的灵敏度明显更高。ADAM10及其使用DμP的检测被证明是AD早期诊断和监测的替代工具，为提高AD患者的生活质量带来了新的令人兴奋的可能性。